Pharmacology for Nurses Unit 28 Review: Diabetic Drugs

Overview of Diabetes

• Diabetes is a chronic metabolic disorder characterized by elevated blood glucose levels (hyperglycemia) resulting from defects in insulin secretion, insulin action, or both
• Two main types of diabetes exist: Type 1 diabetes (insulin-dependent) and Type 2 diabetes (non-insulin-dependent)
  • Type 1 diabetes occurs when the pancreas fails to produce enough insulin due to autoimmune destruction of beta cells
  • Type 2 diabetes develops when the body becomes resistant to insulin's effects, often in combination with reduced insulin production
• Common symptoms of diabetes include increased thirst (polydipsia), frequent urination (polyuria), blurred vision, and unexplained weight loss
• Long-term complications of uncontrolled diabetes can affect various organ systems, leading to cardiovascular disease, nephropathy, neuropathy, and retinopathy
• Diagnosis of diabetes is based on fasting plasma glucose levels, oral glucose tolerance tests, or glycated hemoglobin (HbA1c) measurements
• Management of diabetes involves a combination of lifestyle modifications (diet and exercise), medications, and regular monitoring of blood glucose levels

Types of Diabetic Medications

• Several classes of medications are used to manage diabetes, each with a unique mechanism of action and specific indications
• Insulin is a hormone administered through injections or an insulin pump to replace the body's natural insulin production
  • Various types of insulin exist, including rapid-acting (lispro, aspart), short-acting (regular), intermediate-acting (NPH), and long-acting (glargine, detemir)
• Biguanides (metformin) reduce hepatic glucose production and improve insulin sensitivity in peripheral tissues
• Sulfonylureas (glipizide, glyburide) stimulate pancreatic beta cells to release more insulin
• Thiazolidinediones (pioglitazone, rosiglitazone) enhance insulin sensitivity in peripheral tissues and reduce glucose production in the liver
• Dipeptidyl peptidase-4 (DPP-4) inhibitors (sitagliptin, linagliptin) increase insulin secretion and decrease glucagon production
• Glucagon-like peptide-1 (GLP-1) receptor agonists (liraglutide, exenatide) slow gastric emptying, increase insulin secretion, and decrease glucagon production
• Sodium-glucose cotransporter-2 (SGLT2) inhibitors (canagliflozin, dapagliflozin) promote glucose excretion through the urine by inhibiting renal glucose reabsorption

Mechanism of Action

• Diabetic medications work through various mechanisms to lower blood glucose levels and improve insulin sensitivity
• Insulin directly lowers blood glucose by facilitating glucose uptake into cells and suppressing glucose production in the liver
  • Insulin binds to insulin receptors on cell surfaces, triggering a signaling cascade that leads to the translocation of glucose transporter proteins (GLUT4) to the cell membrane
• Metformin inhibits complex I of the mitochondrial electron transport chain, leading to reduced hepatic glucose production and increased peripheral insulin sensitivity
• Sulfonylureas bind to ATP-sensitive potassium channels on pancreatic beta cells, causing membrane depolarization and calcium influx, which stimulates insulin release
• Thiazolidinediones activate peroxisome proliferator-activated receptor-gamma (PPAR-γ), leading to increased insulin sensitivity and reduced inflammation
• DPP-4 inhibitors prevent the degradation of incretin hormones (GLP-1 and GIP), thereby enhancing their effects on insulin secretion and glucagon suppression
• GLP-1 receptor agonists mimic the effects of endogenous GLP-1, stimulating glucose-dependent insulin secretion, suppressing glucagon release, and slowing gastric emptying
• SGLT2 inhibitors block the reabsorption of glucose in the proximal renal tubules, leading to increased urinary glucose excretion and reduced blood glucose levels

Administration and Dosing

• The route of administration and dosing of diabetic medications varies depending on the specific drug and patient factors
• Insulin is administered subcutaneously using syringes, insulin pens, or an insulin pump
  • Dosing of insulin is individualized based on the patient's blood glucose levels, carbohydrate intake, and physical activity
  • Insulin-to-carbohydrate ratios and correction factors are used to calculate mealtime and correction doses
• Oral medications (metformin, sulfonylureas, thiazolidinediones, DPP-4 inhibitors, SGLT2 inhibitors) are typically taken once or twice daily, with or without food, depending on the specific drug
  • Dosing may be adjusted based on the patient's response and tolerability
• GLP-1 receptor agonists are administered subcutaneously once or twice daily, or once weekly, depending on the specific formulation
• Combination therapy with multiple medications may be necessary to achieve optimal glycemic control
  • Fixed-dose combination products are available to simplify administration and improve adherence
• Dose adjustments may be required in patients with renal or hepatic impairment, as well as in elderly patients or those at risk for hypoglycemia

Side Effects and Contraindications

• Diabetic medications can cause various side effects, some of which may be severe or life-threatening
• Hypoglycemia (low blood glucose) is a common side effect of insulin and sulfonylureas, characterized by symptoms such as shakiness, sweating, confusion, and dizziness
  • Patients should be educated on the recognition and management of hypoglycemia, including the use of glucagon for severe episodes
• Metformin may cause gastrointestinal side effects (nausea, diarrhea, abdominal discomfort) and is contraindicated in patients with severe renal impairment or metabolic acidosis
• Thiazolidinediones can cause fluid retention, leading to edema and weight gain, and are contraindicated in patients with heart failure
• DPP-4 inhibitors may cause headache, nasopharyngitis, and acute pancreatitis in rare cases
• GLP-1 receptor agonists can cause nausea, vomiting, and injection site reactions, and are contraindicated in patients with a history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2
• SGLT2 inhibitors may increase the risk of genital mycotic infections, urinary tract infections, and diabetic ketoacidosis, and are contraindicated in patients with severe renal impairment
• Allergic reactions to any diabetic medication can occur and may manifest as rash, itching, or anaphylaxis

Patient Education and Monitoring

• Patient education is crucial for the successful management of diabetes and the safe use of diabetic medications
• Patients should be taught the proper technique for self-monitoring of blood glucose (SMBG) and the importance of regular monitoring
  • Target blood glucose ranges and HbA1c goals should be individualized based on patient factors and discussed with the healthcare team
• Proper injection technique and rotation of injection sites should be demonstrated for patients using insulin or GLP-1 receptor agonists
• Patients should be educated on the signs and symptoms of hypoglycemia and hyperglycemia, as well as the appropriate actions to take in each situation
• The importance of adhering to prescribed medication regimens, as well as the potential consequences of non-adherence, should be emphasized
• Patients should be encouraged to maintain a healthy lifestyle, including a balanced diet, regular physical activity, and stress management
• Regular follow-up with healthcare providers is essential for monitoring treatment response, adjusting medication doses, and screening for complications
  • Annual eye exams, foot exams, and kidney function tests are recommended for all patients with diabetes

Special Considerations for Nurses

• Nurses play a vital role in the management of diabetes and the administration of diabetic medications
• Thorough medication reconciliation should be performed to identify potential drug interactions and ensure the accuracy of medication lists
• Nurses should be familiar with the various types of insulin and their time-action profiles to ensure proper administration and avoid medication errors
  • Insulin should be inspected for signs of precipitation, discoloration, or expiration before administration
• Blood glucose monitoring results should be accurately documented and communicated to the healthcare team to facilitate timely adjustments in treatment
• Nurses should assess patients for signs and symptoms of hypoglycemia or hyperglycemia and initiate appropriate interventions when necessary
• Proper storage and handling of diabetic medications, particularly insulin, should be ensured to maintain their potency and effectiveness
• Nurses should actively participate in patient education, reinforcing key concepts and providing support for self-management
• Cultural sensitivity and patient preferences should be considered when developing individualized treatment plans and educational strategies

Emerging Treatments and Research

• Advances in diabetes research continue to lead to the development of new medications and treatment strategies
• Newer insulin formulations, such as ultra-long-acting and inhaled insulin, aim to improve convenience and adherence
  • Smart insulin, which can automatically adjust its activity based on blood glucose levels, is currently under investigation
• Dual and triple agonists targeting multiple incretin receptors (GLP-1, GIP, and glucagon) are being developed to provide more potent glucose-lowering effects and potential weight loss benefits
• Stem cell therapy and islet cell transplantation are being explored as potential treatments for Type 1 diabetes, aiming to restore endogenous insulin production
• Advances in continuous glucose monitoring (CGM) systems and closed-loop insulin delivery (artificial pancreas) are improving glycemic control and reducing the burden of diabetes management
• Precision medicine approaches, which tailor treatment based on an individual's genetic profile and other biomarkers, may enable more targeted and effective therapies in the future
• Ongoing research is investigating the role of the gut microbiome in the development and progression of diabetes, as well as the potential for microbiome-based interventions
• Nurses should stay informed about emerging treatments and research to provide up-to-date information and support to patients with diabetes